1. Home
  2. KALA vs EOCN Comparison

KALA vs EOCN Comparison

Compare KALA & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

N/A

Current Price

$3.04

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$1.82

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KALA
EOCN
Founded
2009
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.9M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
KALA
EOCN
Price
$3.04
$1.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 164.5K
6.9K
Earning Date
12-01-2026
11-30-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 67.39
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$2.05
52 Week High
$191.00
$3.80

Technical Indicators

Market Signals
Indicator
KALA
EOCN
Relative Strength Index (RSI) 77.25 23.22
Support Level $2.07 N/A
Resistance Level $3.71 $2.98
Average True Range (ATR) 0.14 0.31
MACD 0.38 -0.06
Stochastic Oscillator 73.26 3.57

Price Performance

Historical Comparison
KALA
EOCN

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: